{"id":5652,"date":"2025-07-28T23:03:13","date_gmt":"2025-07-28T23:03:13","guid":{"rendered":"https:\/\/mailitics.com\/index.php\/2025\/07\/28\/sarepta-duchenne-elevidys-hold-ambulatory\/"},"modified":"2025-07-28T23:03:13","modified_gmt":"2025-07-28T23:03:13","slug":"sarepta-duchenne-elevidys-hold-ambulatory","status":"publish","type":"post","link":"https:\/\/mailitics.com\/index.php\/2025\/07\/28\/sarepta-duchenne-elevidys-hold-ambulatory\/","title":{"rendered":"STAT+: FDA permits use of Sarepta Therapeutics\u2019 Duchenne therapy in younger patients after short-lived halt"},"content":{"rendered":"<p>    STAT+: FDA permits use of Sarepta Therapeutics\u2019 Duchenne therapy in younger patients after short-lived halt<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n    <!-- no image --><br \/>\n \t<BR><br \/>\n<BR><\/BR><\/p>\n<div>\n<p>In a sharp reversal, the Food and Drug Administration on Monday said it was clearing the way for Sarepta Therapeutics to resume shipments of its gene therapy for Duchenne muscular dystrophy to some patients.\u00a0<\/p>\n<p>The therapy, called Elevidys, will once again be available for younger Duchenne patients who can walk.<\/p>\n<p>\u201cThe FDA will continue to work with the sponsor regarding non ambulatory patients, which remains subject to a voluntary hold, following two deaths,\u201d the FDA said in a statement.\u00a0<\/p>\n<p><a href=\"https:\/\/www.statnews.com\/2025\/07\/28\/sarepta-duchenne-elevidys-hold-ambulatory\/?utm_campaign=rss\">Continue to STAT+ to read the full story\u2026<\/a><\/p>\n<\/div>\n<p> \t<BR><br \/>\n <BR><\/BR><br \/>\n    Adam Feuerstein<br \/>\n \t<BR><br \/>\n<BR><\/BR><br \/>\n<a href=\"https:\/\/www.statnews.com\/2025\/07\/28\/sarepta-duchenne-elevidys-hold-ambulatory\/?utm_campaign=rss\">Go to statnews<\/a><br \/>\n \t<BR><br \/>\n <BR><\/BR><\/p>\n","protected":false},"excerpt":{"rendered":"<p>STAT+: FDA permits use of Sarepta Therapeutics\u2019 Duchenne therapy in younger patients after short-lived halt In a sharp reversal, the Food and Drug Administration on Monday said it was clearing the way for Sarepta Therapeutics to resume shipments of its gene therapy for Duchenne muscular dystrophy to some patients.\u00a0 The therapy, called Elevidys, will once [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2194,2154,2216,2155,2678,2152],"tags":[2150],"class_list":["post-5652","post","type-post","status-publish","format-standard","hentry","category-biotech","category-biotechnology","category-breaking-news","category-pharmaceuticals","category-rare-diseases","category-stat","tag-statnews"],"_links":{"self":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/5652"}],"collection":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/comments?post=5652"}],"version-history":[{"count":0,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/posts\/5652\/revisions"}],"wp:attachment":[{"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/media?parent=5652"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/categories?post=5652"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mailitics.com\/index.php\/wp-json\/wp\/v2\/tags?post=5652"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}